Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Feb 10, 2025)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed February 10, 2025
Period End
February 6, 2025
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K filed February 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported fourth-quarter 2024 revenue of $536.6 milliona, up 7.7% from $498.4 million a year earlier, and full-year 2024 revenue of $2.109 billion, up 11.8% from $1.886 billion.

GAAP net income was $117.0 millionb ($3.67 per diluted share) for the quarter and $404.4 million ($12.63 per diluted share) for the year. EBITDA rose 39.3% to $133.5 million in the fourth quarter, with an EBITDA margin of 24.9%, and rose 32.5% to $480.2 million for the full year, with a 22.8% margin. Backlog increased 3.2% to $2,902.2 million at December 31, 2024.

New business momentum softened in the quarter. Net new business awards were $529.7 millionc in the fourth quarter, down 13.8% from $614.7 million a year earlier, giving a net book-to-bill ratio of 0.99x. For the full year, awards totaled $2,230.0 million, a 1.06x book-to-bill ratio, compared with $2,356.7 million in 2023.

Cash and cash equivalents were $669.4 milliond at year-end, and the company repurchased 527,160 shares in the fourth quarter for $174.2 million. For 2025, Medpace guided to revenue of $2.110 billion to $2.210 billion, which the filing describes as growth of 0.0% to 4.8%, GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $11.93 to $12.69.

The guidance assumes a tax rate of 18.0% to 19.0% and 31.7 million diluted shares, and excludes any repurchases after December 31, 2024. On February 6, 2025, the Board approved a $600 million increase to the stock repurchase program.

Key Highlights

  1. Q4 2024 revenue rose 7.7% to $536.6 million; full-year 2024 revenue rose 11.8% to $2,109.1 million.
  2. Q4 2024 EBITDA increased 39.3% to $133.5 million, a 24.9% margin; full-year EBITDA rose 32.5% to $480.2 million.
  3. Q4 2024 GAAP diluted EPS was $3.67 versus $2.46 a year earlier; full-year 2024 diluted EPS was $12.63 versus $8.88.
  4. Net new business awards fell 13.8% to $529.7 million in Q4 2024, with a 0.99x book-to-bill ratio; full-year book-to-bill was 1.06x.
  5. Backlog increased 3.2% to $2,902.2 million as of December 31, 2024.
  6. 2025 guidance: revenue of $2.110 billion to $2.210 billion (0.0% to 4.8% growth), GAAP net income of $378.0 million to $402.0 million, and diluted EPS of $11.93 to $12.69.
  7. Board approved a $600 million increase to the stock repurchase program on February 6, 2025; $134.6 million remained under the prior authorization at year-end 2024.

Frequently Asked Questions

  1. How did Medpace perform in the fourth quarter of 2024?

    Revenue increased 7.7% to $536.6 million, GAAP net income was $117.0 million ($3.67 per diluted share), and EBITDA rose 39.3% to $133.5 million, with a 24.9% EBITDA margin. Total direct costs were $358.3 million and SG&A was $45.4 million.

  2. Did new business awards grow in 2024?

    Not in the fourth quarter. Net new business awards were $529.7 million, down 13.8% from $614.7 million a year earlier, for a 0.99x book-to-bill ratio. For the full year, awards were $2,230.0 million, a 1.06x book-to-bill ratio, compared with $2,356.7 million in 2023.

  3. What is Medpace's 2025 outlook?

    The company forecasts 2025 revenue of $2.110 billion to $2.210 billion, GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $11.93 to $12.69. The guidance assumes a 18.0% to 19.0% tax rate and 31.7 million diluted shares and excludes any buybacks after December 31, 2024.

  4. How is the company returning capital to shareholders?

    In the fourth quarter of 2024, Medpace repurchased 527,160 shares at an average price of $330.43 for $174.2 million, leaving $134.6 million under its authorization at year-end. On February 6, 2025, the Board approved a $600 million increase to the program, which may be executed in the open market, in privately negotiated transactions, or under a Rule 10b5-1 plan, and may be discontinued at any time.

  5. What was the company's financial position at year-end 2024?

    Cash and cash equivalents were $669.4 million, up from $245.4 million at year-end 2023. Total assets were $2,100.9 million, total liabilities were $1,275.3 million, and shareholders' equity was $825.5 million. Advanced billings rose to $710.6 million, and operating cash flow for the full year was $608.8 million.